GSA Capital Partners’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $92K | Buy |
+11,113
| New | +$115K | 0.01% | 1565 |
|
|
2025
Q3 | – | Sell |
-153,968
| Closed | -$982K | – | 1760 |
|
|
2025
Q2 | $982K | Buy |
153,968
+89,348
| +138% | +$511K | 0.07% | 456 |
|
|
2025
Q1 | $314K | Buy |
64,620
+13,350
| +26% | +$111K | 0.03% | 1116 |
|
|
2024
Q4 | $490K | Buy |
+51,270
| New | +$470K | 0.04% | 905 |
|
|
2023
Q1 | – | Sell |
-16,793
| Closed | -$198K | – | 1572 |
|
|
2022
Q4 | $198K | Buy |
+16,793
| New | +$260K | 0.02% | 1191 |
|
|
2022
Q1 | – | Sell |
-5,681
| Closed | -$247K | – | 1512 |
|
|
2021
Q4 | $247K | Buy |
+5,681
| New | +$257K | 0.03% | 1074 |
|
|
2019
Q2 | – | Sell |
-21,670
| Closed | -$1.09M | – | 1511 |
|
|
2019
Q1 | $1.09M | Sell |
21,670
-14,335
| -40% | -$846K | 0.11% | 253 |
|
|
2018
Q4 | $2.13M | Buy |
36,005
+7,800
| +28% | +$503K | 0.25% | 45 |
|
|
2018
Q3 | $1.86M | Sell |
28,205
-42,594
| -60% | -$2.49M | 0.1% | 277 |
|
|
2018
Q2 | $3.58M | Sell |
70,799
-32,700
| -32% | -$1.7M | 0.18% | 71 |
|
|
2018
Q1 | $5.45M | Buy |
103,499
+21,000
| +25% | +$1.05M | 0.29% | 18 |
|
|
2017
Q4 | $3.83M | Buy |
82,499
+68,699
| +498% | +$2.89M | 0.23% | 39 |
|
|
2017
Q3 | $558K | Sell |
13,800
-14,199
| -51% | -$514K | 0.04% | 898 |
|
|
2017
Q2 | $949K | Sell |
27,999
-69,700
| -71% | -$2.15M | 0.06% | 588 |
|
|
2017
Q1 | $2.84M | Buy |
97,699
+2,432
| +3% | +$74K | 0.15% | 123 |
|
|
2016
Q4 | $3.13M | Sell |
95,267
-28,236
| -23% | -$847K | 0.19% | 70 |
|
|
2016
Q3 | $3.89M | Buy |
123,503
+32,615
| +36% | +$948K | 0.21% | 48 |
|
|
2016
Q2 | $2.56M | Sell |
90,888
-41,676
| -31% | -$1.63M | 0.14% | 146 |
|
|
2016
Q1 | $4.82M | Sell |
132,564
-10,004
| -7% | -$353K | 0.31% | 9 |
|
|
2015
Q4 | $5.7M | Buy |
142,568
+17,006
| +14% | +$593K | 0.28% | 22 |
|
|
2015
Q3 | $3.58M | Buy |
125,562
+6,408
| +5% | +$211K | 0.18% | 79 |
|
|
2015
Q2 | $3.93M | Sell |
119,154
-10,200
| -8% | -$316K | 0.15% | 97 |
|
|
2015
Q1 | $3.72M | Buy |
129,354
+26,311
| +26% | +$755K | 0.15% | 100 |
|
|
2014
Q4 | $2.81M | Sell |
103,043
-3,584
| -3% | -$85.4K | 0.2% | 65 |
|
|
2014
Q3 | $2.27M | Buy |
106,627
+23,234
| +28% | +$532K | 0.12% | 169 |
|
|
2014
Q2 | $1.87M | Buy |
83,393
+18,100
| +28% | +$422K | 0.08% | 293 |
|
|
2014
Q1 | $1.65M | Buy |
65,293
+3,900
| +6% | +$98.5K | 0.12% | 165 |
|
|
2013
Q4 | $1.41M | Sell |
61,393
-5,094
| -8% | -$106K | 0.11% | 194 |
|
|
2013
Q3 | $1.27M | Buy |
66,487
+17,493
| +36% | +$312K | 0.1% | 239 |
|
|
2013
Q2 | $706K | Buy |
+48,994
| New | +$709K | 0.08% | 362 |
|
Other funds holding EBS
VCM
PCM
VPM
GSA Capital Partners's EBS Position: Q1 2026 in Review
GSA Capital Partners opened a new position in Emergent Biosolutions (EBS) in Q1 2026: 11,113 shares worth $92K. The stake represents 0.01% of the portfolio and ranks #1565 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in EBS as recently as Q2 2025.
GSA Capital Partners first reported a position in EBS in Q2 2013 and has held it in 30 quarters since. The position peaked at $5.7M in Q4 2015. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- GSA Capital Partners held 11,113 shares of Emergent Biosolutions worth $92K as of Q1 2026.
- Emergent Biosolutions was a new GSA Capital Partners position in Q1 2026.
- Emergent Biosolutions made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1565 holding.
- GSA Capital Partners first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 30 quarters since.
- GSA Capital Partners's Emergent Biosolutions position peaked at $5.7M in Q4 2015.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.